Method for the sysnthesis of compounds of formula I and their uses thereof
    7.
    发明申请
    Method for the sysnthesis of compounds of formula I and their uses thereof 审中-公开
    式I化合物的合成方法及其用途

    公开(公告)号:US20060148760A1

    公开(公告)日:2006-07-06

    申请号:US11362993

    申请日:2006-02-27

    IPC分类号: A61K31/695 A61K31/16

    摘要: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

    摘要翻译: 本发明提供某些化合物,其制备方法,包含该化合物的药物组合物,它们在治疗人或动物病症中的用途。 本发明的化合物可用作晚期糖基化终产物(RAGE)的受体与其配体如晚期糖基化终产物(AGE),S100 /钙粒蛋白/ EN-RAGE,β-淀粉样蛋白和两性蛋白之间相互作用的调节剂 ,以及由RAGE引起的人类疾病的管理,治疗,控制或辅助治疗。 这些疾病或疾病状态包括急性和慢性炎症,糖尿病晚期并发症的发展,例如血管通透性增加,肾病,动脉粥样硬化和视网膜病变,阿尔茨海默病的发展,勃起功能障碍和肿瘤侵袭和转移。

    Benzimidazole derivatives as therapeutic agents

    公开(公告)号:US20060025464A1

    公开(公告)日:2006-02-02

    申请号:US11225277

    申请日:2005-09-13

    IPC分类号: C07D235/04 A61K31/4184

    摘要: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.